logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis

Lopez AMZ, Deen JL, Azman AS, Luguero FJ, Kanungo S, Dutta S, von Seidlein L, Sack DA
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
In addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

Subject Area

vaccinationoutbreakscholera

Languages

English
DOI
10.1093/cid/cix1039
Published Date
21 Nov 2017
PubMed ID
29177437
Journal
Clinical Infectious Diseases
Volume | Issue | Pages
Volume 66, Issue 12, Pages 1960-1971
Issue Date
2017-11-21
Dimensions Badge